Harrow, Inc. HROW
Harrow, Inc. (Nasdaq: HROW) is an ophthalmology drug developer. Its lead program, VEVYE (cyclosporine ophthalmic solution) 0.1% and branded ophthalmic portfolio, is marketed for dry eye disease (VEVYE); portfolio spans ocular anesthesia, retina, post-operative inflammation and others. Its next catalyst on record is OPUVIZ (aflibercept-yszy): Commercial launch (FDA-approved EYLEA biosimilar) (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: OPUVIZ (aflibercept-yszy) — Commercial launch (FDA-approved EYLEA biosimilar) (2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| VEVYE | dry eye disease | small molecule | Approved |
| IHEEZO | ocular surface anesthesia | small molecule | Approved |
| TRIESENCE | ophthalmic inflammatory disease and vitrectomy visualization | small molecule | Approved |
| BYOOVIZ (ranibizumab-nuna) | wet AMD, RVO macular edema, mCNV | antibody | Approved |
| OPUVIZ (aflibercept-yszy) | wet AMD, RVO macular edema, DME, diabetic retinopathy | protein/peptide | Approved |
| BYQLOVI (clobetasol propionate ophthalmic suspension) 0.05% | post-operative ocular inflammation and pain | small molecule | Approved |
| TYRVAYA (varenicline nasal spray 0.03%), being acquired from Viatris | dry eye disease | small molecule | Approved |
Recent results and decisions
- Oct 1, 2026n/a Harrow closes acquisition of TYRVAYA (varenicline nasal spray) for dry eye disease from Viatris for $30 million upfront and up to $70 million in sales milestones.
At closing, Harrow acquired worldwide rights to TYRVAYA, except for Japan. Harrow paid $30 million in cash at closing and may pay up to $70 million in contingent milestone payments tied to TYRVAYA's net sales.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other approved ophthalmology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.